Drugs / Demcizumab
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT02722954 | Jan 2016 → May 2017 | — | OncoMed Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01952249 | Aug 2013 → May 2016 | primary peritoneal carcinoma | OncoMed Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT01189942 | Sep 2010 → Feb 2011 | colorectal cancer | OncoMed Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01189968 | Sep 2010 → Sep 2016 | non-small cell lung carcinoma | OncoMed Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01189929 | Aug 2010 → Dec 2016 | malignant pancreatic neoplasm | OncoMed Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00744562 | Aug 2008 → Nov 2011 | cancer | OncoMed Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT02289898 | Apr 2015 → May 2017 | pancreatic ductal adenocarcinoma | OncoMed Pharmaceuticals, Inc. | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02259582 Comparator | Feb 2015 → Apr 2017 | non-small cell lung carcinoma | OncoMed Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | demcizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02259582 ↗ |
| Known as | OMP-21M18 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01189942 ↗ |
| Action | Inhibit | “Demcizumab may block the growth of cancer stem cells” NCT01189929 ↗ |
| Modality | Monoclonal antibody | “Demcizumab is a humanized monoclonal antibody” NCT01189929 ↗ |
| Route | Intravenous | “weekly intravenous (IV) infusions of OMP-21M18” NCT00744562 ↗ |
| Target | DLL4 | “this phase IB trial of demcizumab, an IgG2 humanized monoclonal antibody directed against DLL4” PMID 29188408 ↗ Feb 2018 |